{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:54:52Z","timestamp":1780106092643,"version":"3.54.0"},"reference-count":42,"publisher":"Japanese Circulation Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1253\/circj.cj-15-0753","type":"journal-article","created":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T17:26:05Z","timestamp":1452187565000},"page":"731-737","source":"Crossref","is-referenced-by-count":33,"title":["Statin Adherence After Ischemic Stroke or Transient Ischemic Attack Is Associated With Clinical Outcome"],"prefix":"10.1253","volume":"80","author":[{"given":"Po-Sheng","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, National Cheng Kung University Hospital and College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Lan","family":"Cheng","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacy and Institute of Biopharmaceutical Sciences, College of Medicine, National Cheng Kung University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yea-Huei","family":"Kao Yang","sequence":"additional","affiliation":[{"name":"Institute of Clinical Pharmacy and Institute of Biopharmaceutical Sciences, College of Medicine, National Cheng Kung University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Heng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Cheng Kung University Hospital and College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. <i>Lancet<\/i> 2008; 371: 1612\u20131623.","DOI":"10.1016\/S0140-6736(08)60694-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hata J, Kiyohara Y. Epidemiology of stroke and coronary artery disease in Asia. <i>Circ J<\/i> 2013; 77: 1923\u20131932.","DOI":"10.1253\/circj.CJ-13-0786"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA. Incidence of the major stroke subtypes: Initial findings from the North East Melbourne stroke incidence study (NEMESIS). <i>Stroke<\/i> 2001; 32: 1732\u20131738.","DOI":"10.1161\/01.STR.32.8.1732"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Petty GW, Brown RD Jr, Whisnant JP, Sick JD, O\u2019Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarction: A population-based study in Rochester, Minnesota, 1975 through 1989. <i>Neurology<\/i> 1998; 50: 208\u2013216.","DOI":"10.1212\/WNL.50.1.208"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: The Oxfordshire Community Stroke Project. <i>Stroke<\/i> 1993; 24: 796\u2013800.","DOI":"10.1161\/01.STR.24.6.796"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Burn JP, Dennis MS, Bamford JM, Sandercock PA, Wade DT, Warlow CP. Long-term risk of recurrent stroke after a first-ever stroke. <i>Stroke<\/i> 1994; 25: 333\u2013337.","DOI":"10.1161\/01.STR.25.2.333"},{"key":"7","unstructured":"7. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, et al; Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). <i>Lancet<\/i> 1994; 344: 1383\u20131389."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. <i>N Engl J Med<\/i> 1998; 339: 1349\u20131357.","DOI":"10.1056\/NEJM199811053391902"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. <i>N Engl J Med<\/i> 1995; 333: 1301\u20131307.","DOI":"10.1056\/NEJM199511163332001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Downs JR, Claerfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS\/TexCAPS: Air Force\/Texas Coronary Atherosclerosis Prevention Study. <i>JAMA<\/i> 1998; 279: 1615\u20131622.","DOI":"10.1001\/jama.279.20.1615"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al; on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial. <i>Lancet<\/i> 2002; 360: 1623\u20131630.","DOI":"10.1016\/S0140-6736(02)11600-X"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-control trial. <i>Lancet<\/i> 2002; 360: 7\u201322.","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Gaulfield M, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial \u2013 Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. <i>Lancet<\/i> 2003; 361: 1149\u20131158.","DOI":"10.1016\/S0140-6736(03)12948-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Izawa A, Kashima Y, Miura T, Ebisawa S, Kitabayashi H, Yamamoto H, et al; on behalf of the ALPS-AMI Investigators. Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction: ALPS-AMI Study. <i>Circ J<\/i> 2015; 79: 161\u2013168.","DOI":"10.1253\/circj.CJ-14-0877"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al; ACC\/AHA Task Force Members. 2014 AHA\/ACC guidelines for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. <i>Circulation<\/i> 2014; 130: e344\u2013e426, doi:10.1161\/CIR.0000000000000134.","DOI":"10.1161\/CIR.0000000000000134"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lee HY, Sakuma I, Ihm SH, Goh CW, Koh KK. Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease. <i>Circ J<\/i> 2014; 78: 281\u2013287.","DOI":"10.1253\/circj.CJ-13-1494"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Uematsu M, Nakamura T, Sugamata W, Kitta Y, Fujioka D, Saito Y, et al. Echolucency of carotid plaque is useful for assessment of residual cardiovascular risk in patients with chronic artery disease who achieve LDL-C goals on statin therapy. <i>Circ J<\/i> 2014; 78: 151\u2013158.","DOI":"10.1253\/circj.CJ-13-0783"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Amarenco P, Labreuche J, Lavall\u00e9e P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: Systematic review and up-to-date meta-analysis. <i>Stroke<\/i> 2004; 35: 2902\u20132909.","DOI":"10.1161\/01.STR.0000147965.52712.fa"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association. <i>Stroke<\/i> 2014; 45: 2160\u20132236.","DOI":"10.1161\/STR.0000000000000024"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. <i>N Engl J Med<\/i> 2006; 355: 549\u2013559.","DOI":"10.1056\/NEJMoa061894"},{"key":"21","unstructured":"21. Stroke Council, American Heart Association; American Stroke Association. Statins after ischemic stroke and transient ischemic attack: An advisory statement from the Stroke Council American Heart Association and American Stroke Association. <i>Stroke<\/i> 2004; 35: 1023."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Wei L, Wang J, Thompson P, Wang S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: A six year follow up study. <i>Heart<\/i> 2002; 88: 229\u2013233.","DOI":"10.1136\/heart.88.3.229"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with nonadherence to statin therapy. <i>Pharmacotherapy<\/i> 2005; 25: 1035\u20131043.","DOI":"10.1592\/phco.2005.25.8.1035"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Poluzzi E, Piccinni C, Carta P, Puccini A, Lanzoni M, Motola D, et al. Cardiovascular events in statin recipients: Impact of adherence to treatment in a 3-year record linkage study. <i>Eur J Clin Phamacol<\/i> 2011; 67: 407\u2013414.","DOI":"10.1007\/s00228-010-0958-3"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. <i>Stroke<\/i> 2007; 38: 2652\u20132657.","DOI":"10.1161\/STROKEAHA.107.487017"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. <i>Lancet<\/i> 2004; 363: 757\u2013767.","DOI":"10.1016\/S0140-6736(04)15690-0"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Vergouwen MD, Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. <i>Stroke<\/i> 2008; 39: 497\u2013502.","DOI":"10.1161\/STROKEAHA.107.488791"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Zanders MM, Haak HR, van Herk-Sukel MP, van de Poll-Franse LV, Johnson JA. Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. <i>Diabetologia<\/i> 2015; 58: 951\u2013960.","DOI":"10.1007\/s00125-015-3497-8"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the national health insurance research database with ischemic stroke cases in Taiwan. <i>Pharmacoepidemiol Drug Saf<\/i> 2011; 20: 236\u2013242.","DOI":"10.1002\/pds.2087"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Goldstein LB, Samsa GP, Matchar DB, Horner RD. Charlson Index comorbidity adjustment for ischemic stroke outcome studies. <i>Stroke<\/i> 2004; 35: 1941\u20131945.","DOI":"10.1161\/01.STR.0000135225.80898.1c"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Stone NJ, Robinson J, Lichtenstein AH, Merz NB, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risks in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. <i>Circulation<\/i> 2014; 129(25 Suppl 2): S1\u2013S45.","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. <i>JAMA<\/i> 2002; 288: 455\u2013461.","DOI":"10.1001\/jama.288.4.455"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Jackvicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndrome. <i>JAMA<\/i> 2002; 288: 462\u2013467.","DOI":"10.1001\/jama.288.4.462"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. <i>Arch Intern Med<\/i> 2005; 165: 1147\u20131152.","DOI":"10.1001\/archinte.165.10.1147"},{"key":"35","unstructured":"35. Schultz JS, O\u2019Donnell JC, McDonough KL, Sasane R, Meyer J. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. <i>Am J Manag Care<\/i> 2005; 11: 306\u2013312."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Haukka J, Niskanen L, Partonen T, L\u00f6nnqvist J, Tiihonen J. Statin usage and all-cause and disease-specific mortality in a nationwide study. <i>Pharmacoepidemiol Drug Saf<\/i> 2012; 21: 61\u201369.","DOI":"10.1002\/pds.2255"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Ho PM, Magid DJ, Shetterly SM, Oslon KL, Maddox TM, Peterson PN, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. <i>Am Heart J<\/i> 2008; 155: 772\u2013779.","DOI":"10.1016\/j.ahj.2007.12.011"},{"key":"38","unstructured":"38. Lingsma HF, Steyerberg EW, Scholte op Reimer WJ, van Domburg R, Dippel DW. Netherlands Stroke Survey Investigators: Statin treatment after a recent TIA or stroke: Is effectiveness shown in randomized clinical trials also observed in everyday clinical practice? <i>Acta Neurol Scand<\/i> 2010; 122: 15\u201320."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Perreault S, Ellia L, Dragomir A, C\u00f4t\u00e9 R, Blais L, B\u00e9rard A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. <i>Am J Med<\/i> 2009; 122: 647\u2013655.","DOI":"10.1016\/j.amjmed.2009.01.032"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Endres M, Laufs U. Discontinuation of statin treatment in stroke patients. <i>Stroke<\/i> 2006; 37: 2640\u20132643.","DOI":"10.1161\/01.STR.0000240690.69406.28"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Hackam DG, Austin PC, Huang A, Juurlink DN, Mamdani MM, Paterson JM, et al. Statins and intracerebral hemorrhage: A retrospective cohort study. <i>Arch Neurol<\/i> 2012; 69: 39\u201345.","DOI":"10.1001\/archneurol.2011.228"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Kao Yang YH. Validation of acute myocardial infarction causes in the National Health Insurance Research Database in Taiwan. <i>J Epidemiol<\/i> 2014; 24: 500\u2013507.","DOI":"10.2188\/jea.JE20140076"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/80\/3\/80_CJ-15-0753\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T04:17:04Z","timestamp":1567484224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/80\/3\/80_CJ-15-0753\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-15-0753","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732010921.793538025","asserted-by":"object"}]},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}